Bayer has acquired Perfuse Therapeutics, including the full rights to the PER-001 intravitreal implant, which is in development for glaucoma and diabetic retinopathy.
June 17, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Bayer Completes Acquisition of Perfuse Therapeutics
Find the latest Optometry and Glaucoma news articles, videos, podcasts, and meeting coverage from medical experts and key opinion…
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and…
FORT LAUDERDALE, Fla. — An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation…
The FDA granted orphan drug designation and fast track designation to Lacripep, according to a press release from TearSolutions.…
Find the latest Presbyopia news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you…
Bayer Completes Acquisition of Perfuse Therapeutics
Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
4 years after snub, GSK partnership helps Spero get Utebzi across FDA finish line
Sanofi, once on FDA course for speedy approval, gains late expansion for Tzield
